US equities
|
MU
$931.24
▲+1.87%
NVDA
$217.23
▼-1.84%
SNDK
$1,394.83
▼-0.61%
AMD
$562.23
▼-1.50%
SPCX
$148.62
▼-2.33%
INTC
$95.37
▼-2.80%
AAPL
$342.00
▼-0.28%
MSFT
$539.44
▲+1.08%
MU
$931.24
▲+1.87%
NVDA
$217.23
▼-1.84%
SNDK
$1,394.83
▼-0.61%
AMD
$562.23
▼-1.50%
SPCX
$148.62
▼-2.33%
INTC
$95.37
▼-2.80%
AAPL
$342.00
▼-0.28%
MSFT
$539.44
▲+1.08%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
BridgeBio Pharma, Inc. - Common Stock
(NQ:
BBIO
)
67.13
+2.19 (+3.37%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BridgeBio Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
October 11, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
October 11, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
October 06, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
October 06, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma (NASDAQ:BBIO) Flashes Perfect Technical Score and Tight Breakout Setup
↗
August 11, 2026
Via
Chartmill
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
October 06, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
October 05, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
October 05, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
↗
September 26, 2026
BridgeBio Pharma (NASDAQ:BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a...
Via
MarketBeat
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
September 23, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 18, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
September 09, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
September 02, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Participate in September Investor Conferences
September 01, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
August 31, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
August 30, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
August 26, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
August 24, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio (BBIO) Q2 2026 Earnings Call Transcript
↗
August 19, 2026
Attruby revenue surged to $222.4 million as three pipeline programs entered regulatory review.
Via
The Motley Fool
Topics
Earnings
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
↗
August 16, 2026
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.
Via
The Motley Fool
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.
↗
August 14, 2026
The company clearly has a winner on its hands with the recently approved Attruby.
Via
The Motley Fool
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
August 14, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
August 13, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 11, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Q2 Earnings Call Highlights
↗
August 10, 2026
BridgeBio Pharma (NASDAQ:BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review...
Via
MarketBeat
Topics
Earnings
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
August 10, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
August 03, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree.
↗
August 02, 2026
Rapid commercial momentum could justify Wall Street's bullish outlook.
Via
The Motley Fool
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
July 22, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
↗
July 13, 2026
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
